Currently, the medical treatment of osteoporosis is based on the use of the specific RANK inhibitors or drugs that can bind bone minerals that disrupt the formation of osteoclasts or initiate their apoptosis. This evidence concerns the gene TNFRSF11A and osteoporosis.